|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Bardeesy N and DePinho RA: Pancreatic
cancer biology and genetics. Nat Rev Cancer. 2:897–909. 2002.
View Article : Google Scholar
|
|
3
|
Korc M: Driver mutations: a roadmap for
getting close and personal in pancreatic cancer. Cancer Biol Ther.
10:588–591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Itakura J, Ishiwata T, Friess H, et al:
Enhanced expression of vascular endothelial growth factor in human
pancreatic cancer correlates with local disease progression. Clin
Cancer Res. 3:1309–1316. 1997.PubMed/NCBI
|
|
5
|
Yamanaka Y: The immunohistochemical
expressions of epidermal growth factors, epidermal growth factor
receptors and c-erbB-2 oncoprotein in human pancreatic cancer.
Nihon Ika Daigaku Zasshi. 59:51–61. 1992.
|
|
6
|
Kornmann M, Ishiwata T, Beger HG and Korc
M: Fibroblast growth factor-5 stimulates mitogenic signaling and is
overexpressed in human pancreatic cancer: evidence for autocrine
and paracrine actions. Oncogene. 15:1417–1424. 1997. View Article : Google Scholar
|
|
7
|
Friess H, Yamanaka Y, Buchler M, Kobrin
MS, Tahara E and Korc M: Cripto, a member of the epidermal growth
factor family, is over-expressed in human pancreatic cancer and
chronic pancreatitis. Int J Cancer. 56:668–674. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamanaka Y, Friess H, Buchler M, et al:
Overexpression of acidic and basic fibroblast growth factors in
human pancreatic cancer correlates with advanced tumor stage.
Cancer Res. 53:5289–5296. 1993.PubMed/NCBI
|
|
9
|
Friess H, Yamanaka Y, Buchler M, et al:
Enhanced expression of transforming growth factor beta isoforms in
pancreatic cancer correlates with decreased survival.
Gastroenterology. 105:1846–1856. 1993.PubMed/NCBI
|
|
10
|
Korc M, Chandrasekar B, Yamanaka Y, Friess
H, Buchier M and Beger HG: Overexpression of the epidermal growth
factor receptor in human pancreatic cancer is associated with
concomitant increases in the levels of epidermal growth factor and
transforming growth factor alpha. J Clin Invest. 90:1352–1360.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishiwata T, Friess H, Buchler MW, Lopez ME
and Korc M: Characterization of keratinocyte growth factor and
receptor expression in human pancreatic cancer. Am J Pathol.
153:213–222. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hruban RH, Maitra A and Goggins M: Update
on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol.
1:306–316. 2008.PubMed/NCBI
|
|
13
|
Garcea G, Neal CP, Pattenden CJ, Steward
WP and Berry DP: Molecular prognostic markers in pancreatic cancer:
a systematic review. Eur J Cancer. 41:2213–2236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rubin JS, Osada H, Finch PW, Taylor WG,
Rudikoff S and Aaronson SA: Purification and characterization of a
newly identified growth factor specific for epithelial cells. Proc
Natl Acad Sci USA. 86:802–806. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Finch PW, Rubin JS, Miki T, Ron D and
Aaronson SA: Human KGF is FGF-related with properties of a
paracrine effector of epithelial cell growth. Science. 245:752–755.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rubin JS, Bottaro DP, Chedid M, et al:
Keratinocyte growth factor. Cell Biol Int. 19:399–411. 1995.
View Article : Google Scholar
|
|
17
|
Nguyen HQ, Danilenko DM, Bucay N, et al:
Expression of keratinocyte growth factor in embryonic liver of
transgenic mice causes changes in epithelial growth and
differentiation resulting in polycystic kidneys and other organ
malformations. Oncogene. 12:2109–2119. 1996.
|
|
18
|
Playford RJ, Marchbank T, Mandir N, et al:
Effects of keratinocyte growth factor (KGF) on gut growth and
repair. J Pathol. 184:316–322. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Watanabe M, Ishiwata T, Nishigai K,
Moriyama Y and Asano G: Overexpression of keratinocyte growth
factor in cancer cells and enterochromaffin cells in human
colorectal cancer. Pathol Int. 50:363–372. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eswarakumar VP, Lax I and Schlessinger J:
Cellular signaling by fibroblast growth factor receptors. Cytokine
Growth Factor Rev. 16:139–149. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mohammadi M, Olsen SK and Ibrahimi OA:
Structural basis for fibroblast growth factor receptor activation.
Cytokine Growth Factor Rev. 16:107–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miki T, Bottaro DP, Fleming TP, et al:
Determination of ligand-binding specificity by alternative
splicing: two distinct growth factor receptors encoded by a single
gene. Proc Natl Acad Sci USA. 89:246–250. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kurban G, Ishiwata T, Kudo M, Yokoyama M,
Sugisaki Y and Naito Z: Expression of keratinocyte growth factor
receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. Oncol
Rep. 11:987–991. 2004.PubMed/NCBI
|
|
24
|
Yoshino M, Ishiwata T, Watanabe M, et al:
Expression and roles of keratinocyte growth factor and its receptor
in esophageal cancer cells. Int J Oncol. 31:721–728.
2007.PubMed/NCBI
|
|
25
|
Yan G, Fukabori Y, McBride G,
Nikolaropolous S and McKeehan WL: Exon switching and activation of
stromal and embryonic fibroblast growth factor (FGF)-FGF receptor
genes in prostate epithelial cells accompany stromal independence
and malignancy. Mol Cell Biol. 13:4513–4522. 1993.PubMed/NCBI
|
|
26
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar
|
|
27
|
Jones L, Ghaneh P, Humphreys M and
Neoptolemos JP: The matrix metalloproteinases and their inhibitors
in the treatment of pancreatic cancer. Ann N Y Acad Sci.
880:288–307. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
John A and Tuszynski G: The role of matrix
metalloproteinases in tumor angiogenesis and tumor metastasis.
Pathol Oncol Res. 7:14–23. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bloomston M, Zervos EE and Rosemurgy AS
II: Matrix metalloproteinases and their role in pancreatic cancer:
a review of preclinical studies and clinical trials. Ann Surg
Oncol. 9:668–674. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harvey SR, Hurd TC, Markus G, et al:
Evaluation of urinary plasminogen activator, its receptor, matrix
metalloproteinase-9, and von Willebrand factor in pancreatic
cancer. Clin Cancer Res. 9:4935–4943. 2003.PubMed/NCBI
|
|
31
|
Kuniyasu H, Ellis LM, Evans DB, et al:
Relative expression of E-cadherin and type IV collagenase genes
predicts disease outcome in patients with resectable pancreatic
carcinoma. Clin Cancer Res. 5:25–33. 1999.PubMed/NCBI
|
|
32
|
Cho K, Ishiwata T, Uchida E, et al:
Enhanced expression of keratinocyte growth factor and its receptor
correlates with venous invasion in pancreatic cancer. Am J Pathol.
170:1964–1974. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fingleton B: Matrix metalloproteinases:
roles in cancer and metastasis. Front Biosci. 11:479–491. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kerkela E and Saarialho-Kere U: Matrix
metalloproteinases in tumor progression: focus on basal and
squamous cell skin cancer. Exp Dermatol. 12:109–125. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mook OR, Frederiks WM and Van Noorden CJ:
The role of gelatinases in colorectal cancer progression and
metastasis. Biochim Biophys Acta. 1705:69–89. 2004.PubMed/NCBI
|
|
36
|
Folgueras AR, Pendas AM, Sanchez LM and
Lopez-Otin C: Matrix metalloproteinases in cancer: from new
functions to improved inhibition strategies. Int J Dev Biol.
48:411–424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hofmann UB, Houben R, Brocker EB and
Becker JC: Role of matrix metalloproteinases in melanoma cell
invasion. Biochimie. 87:307–314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Koshiba T, Hosotani R, Wada M, et al:
Detection of matrix metalloproteinase activity in human pancreatic
cancer. Surg Today. 27:302–304. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Maatta M, Soini Y, Liakka A and
Autio-Harmainen H: Differential expression of matrix
metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in
hepatocellular and pancreatic adenocarcinoma: implications for
tumor progression and clinical prognosis. Clin Cancer Res.
6:2726–2734. 2000.
|
|
40
|
Kimura Y, Kobari M, Yusa T, et al:
Establishment of an experimental liver metastasis model by
intraportal injection of a newly derived human pancreatic cancer
cell line (KLM-1). Int J Pancreatol. 20:43–50. 1996.PubMed/NCBI
|
|
41
|
Parsons SL, Watson SA, Brown PD, Collins
HM and Steele RJ: Matrix metalloproteinases. Br J Surg. 84:160–166.
1997. View Article : Google Scholar
|
|
42
|
Kanno N, Nonomura N, Miki T, et al:
Effects of epidermal growth factor on the invasion activity of the
bladder cancer cell line. J Urol. 159:586–590. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Miyake H, Yoshimura K, Hara I, Eto H,
Arakawa S and Kamidono S: Basic fibroblast growth factor regulates
matrix metalloproteinases production and in vitro invasiveness in
human bladder cancer cell lines. J Urol. 157:2351–2355. 1997.
View Article : Google Scholar
|
|
44
|
Lamoreaux WJ, Fitzgerald ME, Reiner A,
Hasty KA and Charles ST: Vascular endothelial growth factor
increases release of gelatinase A and decreases release of tissue
inhibitor of metalloproteinases by microvascular endothelial cells
in vitro. Microvasc Res. 55:29–42. 1998. View Article : Google Scholar
|
|
45
|
Narita K, Fujii T, Ishiwata T, et al:
Keratinocyte growth factor induces vascular endothelial growth
factor-A expression in colorectal cancer cells. Int J Oncol.
34:355–360. 2009.PubMed/NCBI
|
|
46
|
Yamamoto H, Itoh F, Iku S, et al:
Expression of matrix metalloproteinases and tissue inhibitors of
metalloproteinases in human pancreatic adenocarcinomas:
clinicopathologic and prognostic significance of matrilysin
expression. J Clin Oncol. 19:1118–1127. 2001.
|
|
47
|
Koshiba T, Hosotani R, Wada M, et al:
Involvement of matrix metalloproteinase-2 activity in invasion and
metastasis of pancreatic carcinoma. Cancer. 82:642–650. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chaffer CL, Brennan JP, Slavin JL, Blick
T, Thompson EW and Williams ED: Mesenchymal-to-epithelial
transition facilitates bladder cancer metastasis: role of
fibroblast growth factor receptor-2. Cancer Res. 66:11271–11278.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kwabi-Addo B, Ropiquet F, Giri D and
Ittmann M: Alternative splicing of fibroblast growth factor
receptors in human prostate cancer. Prostate. 46:163–172. 2001.
View Article : Google Scholar : PubMed/NCBI
|
